^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DS-3939
i
Other names: DS-3939, DS-3939a, GT-00A ADC, DS3939, DS 3939, DS3939a, DS 3939a, GT00A ADC, GT 00A ADC
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Daiichi Sankyo, Glycotope
Drug class:
Topoisomerase I inhibitor, TA-MUC1-targeted antibody-drug conjugate
Related drugs:
1year
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=430, Recruiting, Daiichi Sankyo, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
MUC1 (Mucin 1)
|
MUC1 expression
|
DS-3939
over1year
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=430, Not yet recruiting, Daiichi Sankyo, Inc.
New P1/2 trial • Metastases
|
MUC1 (Mucin 1)
|
MUC1 expression
|
DS-3939
Share via
